Molecular Target Synopsis
Domains and Structures
Drugs and Clinical Candidates
Ligand Efficiency Plot
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
Germline Genetics

PTGES2 (Q9H7Z7) - Overview - Molecular Target Synopsis


PTGES2, Prostaglandin E synthase 2
Enzyme Classification
UniProt Q9H7Z7

Also Known as PGES2_HUMAN, PTGES2, C9orf15, PGES2

Isomerase that catalyzes the conversion of PGH2 into the more stable prostaglandin E2 (PGE2). Homodimer. May interact with CEBPB (By similarity). Interacts with EXOSC10.

Isoforms / Transcripts (Protein Coding)

Sub-cellular localization

UniProt: PTGES2 is active in the following subcellular-locations: cytoplasm, golgi apparatus membrane, perinuclear region.
GO terms: PTGES2 is active in the following subcellular-locations: azurophil granule lumen, cytosol, extracellular region, Golgi membrane, integral component of membrane, mitochondrion, nucleus, perinuclear region of cytoplasm.

GO terms

Gene Copy Number Variation

In COSMIC - Cell Lines Project PTGES2 has gain in 0 cell-lines, loss in 1 cell-lines and no signal in 1004 cell-lines. (see details)

Gene Expression

In NCI60, the highest expressing cell lines are: HCC_2998, SN12C, SK_MEL_5

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: EPLC-272H, BFTC-905, LS 174T

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: SK-N-SH, A549, K562

(see details)

3D Structures

At greater than 90% identity similarity to PTGES2 there are:
2 structures (8 chains) solved
2 are solved in complex with at least one small molecule ligand
1 are solved with an approved drug

PTGES2 is solved in complex with the approved drug(s):


(see details)
Molecular Target 3D Synopsis

Screening and Chemistry

PTGES2 has been screened with 290 compounds (312 bioactivities), 96 compounds have bioactivities that show binding affinity of <= 500nM (96 bioactivities). (see details)